Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma

Author： Kang Byung   Kim Won   Kim Chul   Jang Geundoo   Lee Sung   Choi Yoon   Lee Dae   Kim Sang   Kim Shin   Ryu Jin-Sook   Huh Jooryung   Lee Jung   Suh Cheolwon  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.28, Iss.4, 2010-08, pp. : 516-522

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preliminary Experience with Yttrium-90-labelled Rituximab (Chimeric Anti CD-20 Antibody) in Patients with Relapsed and Refractory B Cell Non-Hodgkins Lymphoma

By  

Current Radiopharmaceuticals, Vol. 9, Iss. 2, 2016-08 ,pp. : 160-168

Bentham Science Publishers

Access to resources Recommend Favorite

Zevalin TM: 90 Yttrium Labeled Anti-CD20 (Ibritumomab Tiuxetan), a New Treatment for Non-Hodgkin's Lymphoma

By  

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 4, 2001-12 ,pp. : 341-349

Bentham Science Publishers

Access to resources Recommend Favorite

Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma

By Chen Yi-Bin   Batchelor Tracy   Li Shuli   Hochberg Ephraim   Brezina Mark   Jones Sooae   Del Rio Candice   Curtis Morgan   Ballen Karen K.   Barnes Jeffrey   Chi Andrew S.   Dietrich Jorg   Driscoll Jessica   Gertsner Elizabeth R.   Hochberg Fred   LaCasce Ann S.   McAfee Steven L.   Spitzer Thomas R.   Nayak Lakshmi   Armand Philippe  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 226-233

Blackwell Publishing

Access to resources Recommend Favorite

Ibritumomab tiuxetan Y-90 plus high-dose BEAM chemotherapy was well tolerated in older patients with non-Hodgkin's lymphoma

By  

Inpharma, Vol. 1, Iss. 1617, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study

By  

Cancer, Vol. 121, Iss. 19, 2015-10 ,pp. : 3465-3471

Blackwell Publishing

Access to resources Recommend Favorite